Latest news

FINANCIAL SUMMARY Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388) Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK

Är du driven och motiveras av varierande arbetsuppgifter? Har du erfarenhet från producerande noterat bolag? Lockas du av en expansiv innovativ verksamhet? Då kan du vara den Business Controller som Nanologica söker! Vad får dig att trivas hos uppdragsgivaren Hos Nanologica får du jobba på ett bolag som vill förbättra för mänskligheten genom att bidra till att öka tillgängligheten till insulin och andra livsnödvändiga mediciner för patienter världen över. Bolaget är i början av en

As a result of Nanologica’s product in preparative chromatography, NLAB Saga®, reaching internal quality requirements, silica is now delivered to a customer in Latin America for production of diabetes drugs. The customer is a latin-american pharmaceutical manufacturer that manufactures, among other things, insulin and insulin analogues. This delivery refers to silica for the production of insulin. The delivery is made against a recent order with an order value of about TSEK 300. ”We have for

Nanologica will participate at Redeye Growth Day 2023 on June 1st. CEO Andreas Bhagwani will present at 11.35. The In Focus interview is live broadcasted at https://www.redeye.se/events/871323/redeye-growth-day

In order to create the best conditions for success in preparative chromatography, the company’s operations are focused on Chromatography and the Drug Development operations are down-prioritized and placed in subsidiaries for future opportunities. The management team is adapted to reflect this and CSO Gary Pitcairn and VP Drug Development Ulf Ericsson will leave the company for new opportunities. “ Our work within Drug Development has reached a point where continued development is very resource-intensive and we